Oxford Cannabinoid Technologies Holdings Plc
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a OCTHF research report →
Price Chart
About the company
Oxford Cannabinoid Technologies Holdings Plc operates as a biopharmaceutical company, specializing in the discovery, development, and eventual market launch of cannabinoid-derived prescription medications. Its leading experimental drug, OCT461201, is a selective CB2 receptor agonist formulated as a solid oral dose. This compound is currently in the early, pre-clinical phase of development, being explored for its potential to alleviate visceral pain linked to Irritable Bowel Syndrome (IBS), alongside various neuropathic pain disorders like post-herpetic neuralgia.
- CEO
- Clarissa Ann Sowemimo-Coker
- IPO
- 2021
- Employees
- 5
- HQ
- London, GB
Get TickerSpark's AI analysis on OCTHF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $3.05M
- P/E
- -0.19
- PEG
- -0.00
- P/S
- 0.00
- P/B
- 0.28
- EV/EBITDA
- 0.15
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -86.76%
- ROIC
- -152.06%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-4,303,608-6668.5%
- Op Income
- $-7,037,609
- Net Income
- $-5,945,050-15.6%
- EPS
- $-0.01-14.8%
- OCF Growth
- -27.8%
- FCF Growth
- -27.8%
- 52W High
- $0.04
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 3.63
- RSI (14)
- 47
- Avg Volume
- 6.19K
No earnings-call transcripts are available for OCTHF yet.
- Free Float
- 67.1%
- Shares Outstanding
- 1.09B
- Float Shares
- 730.42M
Our OCTHF coverage
Recent articles, reports, and earnings notes.
No research on OCTHF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate OCTHF report →British biotech joins LSE exodus
proactiveinvestors.co.uk · May 8
Oxford Cannabinoid Technologies files patent application for pain relief drug
proactiveinvestors.com · Jan 10
Oxford Cannabinoid appoints CMO Dr Tim Corn to the board
proactiveinvestors.com · Nov 14
Oxford Cannabinoid Technologies delighted with phase 1 outcome for pain drug
proactiveinvestors.com · Oct 24
Oxford Cannabinoid Technologies shares jumo 6% on successful completion of phase I study
proactiveinvestors.com · Oct 10
Oxford Cannabinoid readies for next stage as it safely navigates phase I stduy
proactiveinvestors.com · Oct 10
Oxford Cannabinoid Technologies completes final dose in phase I trial of lead asset
proactiveinvestors.com · Sep 25
Oxford Cannabinoid Technologies hails defining year as clinical trials remain on track
proactiveinvestors.co.uk · Aug 31
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.